Year Founded
2002
Ownership
Private
Employees
~1000
Stage
Preclinical
Modalities
Autologous cell therapySmall molecule

Shanghai GeneChem General Information

Company provides genomic sequencing and cellular analysis services. Recent research shows CHAC1 blockade suppresses progression of lung adenocarcinoma by interfering with glucose metabolism via hijacking PKM2 nuclear translocation.

Contact Information

Website
Primary Industry
Biotech
Corporate Office

Drug Pipeline

No pipeline data available

For full access to Shanghai GeneChem's pipeline data

Book a demo

Key Partnerships

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Shanghai GeneChem Funding

Deal TypeDateAmountStatusStage
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Shanghai GeneChem's complete valuation and funding history, request access »

Shanghai GeneChem Investors

Humanwell Healthcare Group
Investor Type: Venture Capital
Holding: Minority
Principle Capital
Investor Type: Venture Capital
Holding: Minority
Shanghai Free Trade Zone Equity Fund Management
Investor Type: Venture Capital
Holding: Minority
Investor Name
Investor Type
Holding
Investor Name
Investor Type
Holding
You're viewing 3 of 5 investors. Get the full list »